07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results.

The trial met its key secondary endpoint of overall survival, demonstrating that the combination therapy "significantly reduced" the risk of death compared with the standard of care, daratumumab plus BorDex.

The full trial results, including safety data, will be presented at the upcoming American Society of Hematology Annual Meeting on Dec. 9.

The company will share the data with health authorities to support regulatory filings.

GSK said it plans to start a phase 3 study in newly diagnosed transplant-ineligible multiple myeloma by year-end as part of the DREAMM program.